(Q28262476)

23 March 2017

1 reference

4

Toos Daemen

1 reference

23 March 2017

7

Jan Wilschut

1 reference

23 March 2017

1

Anke Huckriede

1 reference

23 March 2017

author name string

Laura Bungener

2

1 reference

23 March 2017

Toon Stegmann

3

1 reference

23 March 2017

Jeroen Medema

5

1 reference

23 March 2017

Abraham M Palache

6

0 references

Abraham M. Palache

6

1 reference

23 March 2017

language of work or name

English

0 references

publication date

8 July 2005

0 references

July 2005

1 reference

23 March 2017

1 reference

23 March 2017

volume

23 Suppl 1

0 references

23

1 reference

23 March 2017

page(s)

S26-38

0 references

S26-S38

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

23 March 2017

1 reference

New options for prevention and control of influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Economic evaluation of influenza vaccination. Assessment for The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Public health. Will vaccines be available for the next influenza pandemic?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Development of a mammalian cell (Vero) derived candidate influenza virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Influenza vaccination in 2000: recommendations and vaccine use in 50 developed and rapidly developing countries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

The global agenda on influenza surveillance and control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

The influenza vaccine licensing process.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Annual revaccination against influenza and mortality risk in community-dwelling elderly persons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Antibody induction by influenza vaccines in the elderly: a review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Impaired antibody response to influenza vaccine in institutionalized elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Immunity to influenza in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Influenza A virus specific T cell immunity in humans during aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

The unmet need in the elderly: designing new influenza vaccines for older adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Preparation, properties, and applications of reconstituted influenza virus envelopes (virosomes).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Infectious entry pathway of influenza virus in a canine kidney cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Endocytosis of influenza viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

How Viruses Enter Animal Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Fusion of influenza virus in an intracellular acidic compartment measured by fluorescence dequenching

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

A spring-loaded mechanism for the conformational change of influenza hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Structure of influenza haemagglutinin at the pH of membrane fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

N- and C-terminal residues combine in the fusion-pH influenza hemagglutinin HA(2) subunit to form an N cap that terminates the triple-stranded coiled coil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Cellular cytoplasmic delivery of a polypeptide toxin by reconstituted influenza virus envelopes (virosomes).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Formation of virosomes from influenza subunits and liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

The biochemistry and cell biology of antigen processing and presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Virosome-mediated delivery of protein antigens to dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Immunobiology of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Kinetics of costimulatory molecule expression by T cells and dendritic cells during the induction of tolerance versus immunity in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Immunogenicity of new virosome influenza vaccine in elderly people

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Clinical experience with inactivated, virosomal influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Inactivated virosome hepatitis A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Immunogenicity of IRIV- versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

A two-phase model of B-cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Synthetic lipopeptide adjuvants and Toll-like receptor 2--structure-activity relationships

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Lipopeptide vaccines--yesterday, today, and tomorrow

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Regulation of the immune response by antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Maturation, activation, and protection of dendritic cells induced by double-stranded RNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Recognition of single-stranded RNA viruses by Toll-like receptor 7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

Influenza infection in ferrets: role of serum antibody in protection and recovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

inferred from DOI database lookup

7 January 2021

based on heuristic

Molecular basis for the generation in pigs of influenza A viruses with pandemic potential

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

inferred from DOI database lookup

7 January 2021

based on heuristic

Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.026

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2005.04.026

1 reference